tradmap

NVAX Financials Novavax Inc

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has declined 17.2% per year over the past 5 years.

Financial health

  • Total debt ($244M) exceeds cash ($241M); net debt is $4M.
  • Operating income covered interest expense 20× in the latest year.
  • Total debt is 0.5× EBITDA.
Revenue & net income
-$2B $119M $2B $0 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
-58% 18% 93% 0% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Return on equity & assets (ROE / ROA)
-345% 2352% 5048% 0% 2011 2013 2015 2017 2019 2021 2023 2025
ROEROA
Free cash flow (CFO − capex)
-$277M -$6M $265M $0 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $758M $2B 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$714M $135M $985M $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MROEROAFCFTotal debtCash
2025 $1.1B $440M 93.5% 40.3% -344.7% 37.4% — $244M $241M
2024 $682M -$187M 70.3% -36.5% 30.1% -12.0% — — $530M
2023 $984M -$545M 65.1% -57.6% 76.0% -30.3% — — $569M
2022 $2.0B -$658M 54.5% -32.5% 103.8% -29.1% — — $1.3B
2021 — -$1.7B — — 495.8% -67.7% $265M — $1.5B
2020 — -$418M — — -66.7% -26.4% -$97M — $553M
2019 — -$133M — — 71.3% -76.7% -$138M — $79M
2018 — -$185M — — 110.0% -88.8% -$186M — $70M
2017 — -$184M — — 180.6% -60.8% -$149M — $106M
2016 — -$280M — — 5048.1% -71.0% -$277M — $144M
2015 — -$157M — — -53.6% -40.7% -$144M — $93M
2014 — -$83M — — -36.1% -30.1% — — $32M
2013 — -$52M — — -25.6% -22.1% — — $119M
2012 — -$29M — — -35.5% -27.9% -$23M — $17M
2011 — -$19M — — -36.0% -29.1% -$24M — $14M

Valuation over time

How the market has priced NVAX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 2.1 4.1 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/E
Price / sales (P/S)
0.0 1.3 2.5 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/S

Frequently asked questions

Is NVAX growing its revenue and profit?

Over the past 5 years, Novavax Inc's revenue has declined 17.2% per year. These are computed facts, not advice.

How much debt does NVAX have?

As of FY2025, Novavax Inc reported $244M of total debt against $241M of cash; operating income covered interest expense 20×.

What is NVAX's profit margin?

In FY2025, gross margin was 93.5%, operating margin 40.3%, and net margin 39.2%.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.